Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3781-e3789. doi: 10.1210/clinem/dgac355.
There are concerns for COVID-19 vaccination in triggering thyroid autoimmunity and causing thyroid dysfunction. Also, data on the effect of preexisting thyroid autoimmunity on the efficacy of COVID-19 vaccination are limited.
We evaluated the effect of COVID-19 vaccination on thyroid function and antibodies, and the influence of preexisting thyroid autoimmunity on neutralizing antibody (NAb) responses.
Adults without a history of COVID-19/thyroid disorders who received the COVID-19 vaccination during June to August 2021 were recruited. All received 2 doses of vaccines. Thyrotropin (TSH), free thyroxine (fT4), free 3,5,3'-triiodothyronine (fT3), antithyroid peroxidase (anti-TPO), and antithyroglobulin (anti-Tg) antibodies were measured at baseline and 8 weeks post vaccination. NAb against SARS-CoV-2 receptor-binding domain was measured.
A total of 215 individuals were included (129 [60%] BNT162b2; 86 [40%] CoronaVac recipients): mean age 49.6 years, 37.2% men, and 12.1% anti-TPO/Tg positive at baseline. After vaccination, TSH did not change (P = .225), but fT4 slightly increased (from 12.0 ± 1.1 to 12.2 ± 1.2 pmol/L [from 0.93 ± 0.09 to 0.95 ± 0.09 ng/dL], P < .001) and fT3 slightly decreased (from 4.1 ± 0.4 to 4.0 ± 0.4 pmol/L [from 2.67 ± 0.26 to 2.60 ± 0.26 pg/mL], P < .001). Only 3 patients (1.4%) had abnormal thyroid function post vaccination, none clinically overt. Anti-TPO and anti-Tg titers increased modestly after vaccination (P < .001), without statistically significant changes in anti-TPO/Tg positivity. Changes in thyroid function and antithyroid antibodies were consistent between BNT162b2 and CoronaVac recipients, except for greater anti-TPO titer increase post BNT162b2 (P < .001). NAb responses were similar between individuals with and without preexisting thyroid autoimmunity (P = .855).
COVID-19 vaccination was associated with a modest increase in antithyroid antibody titers. Anti-TPO increase was greater among BNT162b2 recipients. However, there was no clinically significant thyroid dysfunction post vaccination. NAb responses were not influenced by preexisting thyroid autoimmunity. Our results provide important reassurance for people to receive the COVID-19 vaccination.
人们担心 COVID-19 疫苗接种会引发自身免疫性甲状腺疾病并导致甲状腺功能障碍。此外,关于预先存在的自身免疫性甲状腺疾病对 COVID-19 疫苗接种效果的影响的数据有限。
我们评估了 COVID-19 疫苗接种对甲状腺功能和抗体的影响,以及预先存在的自身免疫性甲状腺疾病对中和抗体(NAb)反应的影响。
招募了 2021 年 6 月至 8 月期间未患有 COVID-19/甲状腺疾病史且接受 COVID-19 疫苗接种的成年人。所有患者均接受 2 剂疫苗接种。在基线和接种疫苗后 8 周测量促甲状腺激素(TSH)、游离甲状腺素(fT4)、游离三碘甲状腺原氨酸(fT3)、抗甲状腺过氧化物酶(anti-TPO)和抗甲状腺球蛋白(anti-Tg)抗体。测量针对 SARS-CoV-2 受体结合域的 NAb。
共纳入 215 名患者(129 名[60%]接受 BNT162b2 接种;86 名[40%]接受 CoronaVac 接种):平均年龄 49.6 岁,37.2%为男性,基线时 12.1%抗-TPO/Tg 阳性。接种疫苗后,TSH 没有变化(P=0.225),但 fT4 略有增加(从 12.0±1.1 到 12.2±1.2 pmol/L[从 0.93±0.09 到 0.95±0.09 ng/dL],P<0.001),fT3 略有下降(从 4.1±0.4 到 4.0±0.4 pmol/L[从 2.67±0.26 到 2.60±0.26 pg/mL],P<0.001)。只有 3 名患者(1.4%)在接种疫苗后出现甲状腺功能异常,均无临床意义。接种疫苗后抗-TPO 和抗-Tg 滴度略有增加(P<0.001),但抗-TPO/Tg 阳性率无统计学意义变化。BNT162b2 和 CoronaVac 接种者之间甲状腺功能和抗甲状腺抗体的变化一致,除了 BNT162b2 接种后抗-TPO 滴度增加更大(P<0.001)。预先存在的自身免疫性甲状腺疾病对 NAb 反应无影响(P=0.855)。
COVID-19 疫苗接种与抗甲状腺抗体滴度的适度增加有关。BNT162b2 接种者的抗-TPO 增加更为明显。然而,接种疫苗后无明显甲状腺功能障碍。预先存在的自身免疫性甲状腺疾病对 NAb 反应没有影响。我们的结果为人们接种 COVID-19 疫苗提供了重要保证。